Dalrada Technology Group, Inc. Material Event: A Critical Financing Deal

This summary breaks down a significant development for Dalrada Technology Group, Inc., explaining the key details and potential implications for investors in clear, straightforward language.

---

1. Event Description

Dalrada's healthcare subsidiary, Genefic Inc., has secured a substantial financing package from IBS Investment Bank. This package includes up to $20 million in financial guarantees, meaning IBS promises to cover Genefic's obligations if Genefic cannot, and a $5 million revolving credit facility, which acts as a flexible line of credit for daily operations.

Crucially, to obtain this financing, Dalrada Technology Group, Inc. (the parent company) pledged substantially all of its assets, including all ownership stakes in its other subsidiaries, as collateral. This means if Genefic defaults on its obligations, Dalrada could lose its entire asset base and all its other businesses. Additionally, Dalrada's CEO, Brian Bonar, provided an unlimited personal guarantee for these obligations, directly linking his personal finances to the deal.

As part of the agreement, Dalrada also paid $140,000 in upfront cash fees, issued a $165,000 promissory note (a written promise to pay a specific sum by a certain date), and granted IBS Investment Bank a warrant for 5% ownership in Genefic (giving the bank the right to buy Genefic shares at a set price).

This financing aims to boost Genefic's healthcare operations, particularly its specialty pharmacy services, and provide working capital for growth. Dalrada's Board of Directors approved the deal, believing it will enable Genefic to expand and operate more effectively, ultimately benefiting the broader Dalrada family of companies. The high-risk nature of the collateral suggests a strong need for this capital to fuel Genefic's strategic initiatives or address operational requirements.

2. Event Date/Timeline

Dalrada signed the agreements on December 31, 2025, and officially announced the transaction in an SEC filing on January 21, 2026.

3. Financial Components

This transaction involves several key financial elements:

• Financing Package: Genefic Inc. secured up to $20 million in financial guarantees and a $5 million revolving credit facility from IBS Investment Bank, totaling a potential $25 million.
• Collateral: Dalrada Technology Group, Inc. pledged substantially all of its assets, including all its ownership stakes in other subsidiaries, as collateral for these obligations.
• Personal Guarantee: Dalrada's CEO, Brian Bonar, provided an unlimited personal guarantee for these obligations.
• Upfront Fees: Dalrada paid $140,000 in upfront cash fees.
• Promissory Note: Dalrada issued a $165,000 promissory note as part of the upfront consideration.
• Equity Warrant: Dalrada granted a warrant for 5% ownership in Genefic to IBS Investment Bank.
• Other Terms: The company didn't provide specific details about interest rates, repayment schedules, or the exact rules (covenants) governing the agreement in this filing. However, these are standard and crucial components of any such financing deal.

4. Impact Assessment

This financing represents a highly significant event that introduces substantial risk for Dalrada shareholders.

On one hand, the funding could enable substantial growth for Genefic's healthcare services, potentially increasing its revenue and market presence. This success could, in turn, benefit Dalrada's overall financial performance.

However, the risks are considerable. By pledging virtually all its assets and all its other subsidiaries as collateral, Dalrada has made its entire future dependent on Genefic's performance. If Genefic struggles to meet its obligations or defaults on the financing, Dalrada could lose all its pledged assets, including its other businesses, potentially leading to severe financial distress or even bankruptcy for the parent company.

The CEO's unlimited personal guarantee, while demonstrating commitment, also creates a significant potential conflict of interest. His personal financial exposure might influence his decisions regarding Genefic, potentially prioritizing its debt repayment or short-term performance in ways that may not always align perfectly with the long-term interests of Dalrada's other subsidiaries or all Dalrada shareholders.

Who/What is Affected:

• Employees (especially at Genefic): This financing should provide stability and resources, potentially leading to growth and new opportunities within Genefic.
• Customers (of Genefic): They could benefit from expanded or improved healthcare services.
• Investors (of Dalrada): This is where the impact is most critical. Your investment in Dalrada is now heavily tied to Genefic's success. The significantly increased risk means that if Genefic fails, Dalrada shareholders could face a substantial, potentially total, loss of their investment. The CEO's personal guarantee and the potential conflicts of interest are also crucial factors to monitor.
• Competitors (in healthcare/specialty pharmacy): Genefic now has greater financial capacity, which could make it a stronger competitor in its market.

Immediately, Genefic will utilize these funds to support its healthcare operations, likely for expanding services, increasing inventory, or marketing efforts.

Looking ahead, investors should focus on Genefic's financial performance. Closely scrutinize Dalrada's future financial reports, paying particular attention to Genefic's revenue growth, profitability, cash flow, and its ability to service this new debt. Any signs of financial distress or breaches of the strict covenants associated with these agreements could trigger severe consequences for Dalrada. Investors should also monitor any further announcements regarding the CEO's role or potential related-party transactions given his personal guarantee.

5. Key Takeaways for Investors

Here are the critical points for investors to consider:

• Extreme Risk Profile: This is not a routine financing deal. Dalrada has essentially mortgaged all its assets and all its other businesses to secure this funding for Genefic. This significantly elevates the risk profile of Dalrada stock. While Genefic's success could bring high rewards, its struggles carry a very real risk of significant, potentially total, loss for Dalrada shareholders.
• CEO's Personal Stake & Conflict: Brian Bonar's unlimited personal guarantee is highly unusual. While it signals commitment, it also creates a direct financial link between his personal wealth and Genefic's success. This could influence his decisions, potentially prioritizing Genefic's short-term needs over the broader, long-term interests of all Dalrada shareholders or its other subsidiaries.
• Monitor Genefic Closely: Your investment in Dalrada is now heavily dependent on the performance of its healthcare subsidiary, Genefic. Pay close attention to any news, financial updates, or operational reports specifically about Genefic.
• Significant Upfront Costs: The substantial upfront fees ($140,000 cash, a $165,000 promissory note, and a warrant for 5% of Genefic's ownership) represent costs that Genefic's future performance must justify.
• Strict Covenants: The agreements include strict rules (covenants) that Genefic must adhere to, likely covering financial performance targets and restrictions on other activities. Any breach could trigger immediate and severe problems for Dalrada.
• Thorough Due Diligence: Given the high stakes, it is even more crucial to read the official SEC 8-K filing and any subsequent financial reports in detail. Understand the full implications of this financing structure before making any investment decisions. The potential for reward in this situation is matched by an equally significant risk of loss.